| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Erasmus Medical Center |
| Information provided by: | Erasmus Medical Center |
| ClinicalTrials.gov Identifier: | NCT00410293 |
Purpose
Diagnostic uncertainty in patients with complaints of shortness of breath presenting to the Emergency Department of a hospital may delay treatment and proper care. In patients with shortness of breath due to heart failure increased plasma levels of NT-pro-B-type natriuretic peptide (NT-proBNP) can be demonstrated. The use of NT-proBNP as a biomarker for heart failure in patients presenting to the emergency department with dyspnea might improve care and reduce length of hospital stay.
To investigate the effect of NT-proBNP testing on patient care and time to discharge the NT-proBNP test will be randomized. In patients in the study group, the NT-proBNP plasma level is determined at admission and the physician in charge will immediately receive the result of the test. In patients in the control group blood will be sampled but the physician will recieve no information on the NT-proBNP plasma level.
In our study we will investigate the effect of introduction of NT-proBNP as biomarker for heart failure on treatment, time to discharge and costs.
| Condition | Intervention |
|
Heart Failure Dyspnea |
Procedure: NT-proBNP testing |
| MedlinePlus related topics: | Breathing Problems Heart Failure |
| ChemIDplus related topics: | Nesiritide Proline |
| Study Type: | Interventional |
| Study Design: | Diagnostic, Randomized, Single Blind, Placebo Control, Single Group Assignment, Efficacy Study |
| Official Title: | NT-proBNP Testing in Patients Presenting to the Emergency Department With Acute Dyspnea: Evaluation of Effects on Treatment, Hospitalisation Rate and Costs |
| Estimated Enrollment: | 500 |
| Study Start Date: | December 2004 |
| Estimated Study Completion Date: | August 2006 |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Netherlands | |||||
| Erasmus MC | |||||
| Rotterdam, Netherlands, 3015 CE | |||||
| Erasmus Medical Center |
| Principal Investigator: | Anton H. van den Meiracker, MD, PhD | Erasmus MC, Rotterdam, the Netherlands |
More Information
| Study ID Numbers: | MEC-2004-201 |
| First Received: | December 11, 2006 |
| Last Updated: | December 11, 2006 |
| ClinicalTrials.gov Identifier: | NCT00410293 |
| Health Authority: | Netherlands: Medical Ethics Review Committee (METC) |
|
|
|
|
|
|
